{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:32:40Z","timestamp":1794004360622,"version":"4.8.0"},"reference-count":153,"publisher":"Bentham Science Publishers Ltd.","issue":"22","funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council for Medical Research (ICMR), New Delhi","doi-asserted-by":"publisher","award":["45\/05\/2019-PHA-BMS"],"award-info":[{"award-number":["45\/05\/2019-PHA-BMS"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council for Medical Research (ICMR), New Delhi","doi-asserted-by":"publisher","award":["58\/33\/2020-PHA\/BMS"],"award-info":[{"award-number":["58\/33\/2020-PHA\/BMS"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CTMC"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>The management of Alzheimer\u2019s disease is challenging due to its complexity. However, the currently approved and marketed treatments for this neurodegenerative disorder revolves around cholinesterase inhibitors and glutamate regulators or the combination of these agents. Despite the prompt assurance of many new drugs, several agents were unsuccessful, especially in phase II or III trials, not meeting efficacy endpoints.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>The execution of effective treatment approaches through further trials investigating a rational combination of agents is necessitude for Alzheimer\u2019s disease.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Method:<\/jats:title>\n<jats:p>For this review, more than 248 relevant scientific papers were considered from a variety of databases (Scopus, Web of Science, Google Scholar, Sciencedirect, and Pubmed) using the keywords Alzheimer\u2019s disease, amyloid-\u03b2, combination therapies, cholinesterase inhibitors, dementia, glutamate regulators, AD hypothesis.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Result and Discussion:<\/jats:title>\n<jats:p>The researcher's intent for either developing a disease-modifying therapeutic means for aiming in the early phases of dementia and\/or optimizing the available symptomatic treatments principally committed to the more advanced stages of Alzheimer\u2019s. Since Alzheimer possesses multifactorial pathogenesis, designing a multimodal therapeutic intervention for targeting different pathological processes of dementia may appear to be the most practical method to alter the course of disease progression.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>The combination approach may even allow for providing individual agents in lower doses, with reducible cost and side effects. Numerous studies on combination therapy predicted better clinical efficacy than monotherapy. The below literature review highlights the major clinical studies (both symptomatic and disease-modifying) conducted in the past decade on combination therapy to combat the cognitive disorder.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1568026622666220907114443","type":"journal-article","created":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T11:19:20Z","timestamp":1662722360000},"page":"1849-1867","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Combination Therapy for the Treatment of Alzheimer\u2019s Disease: Recent\nProgress and Future Prospects"],"prefix":"10.2174","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8190-8106","authenticated-orcid":true,"given":"Ekta","family":"Shirbhate","sequence":"first","affiliation":[{"name":"Institute of Pharmaceutical Sciences, Guru Ghasidas University, Bilaspur, 495 009, (C.G.), India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0392-3308","authenticated-orcid":true,"given":"Vijay K.","family":"Patel","sequence":"additional","affiliation":[{"name":"Institute of Pharmaceutical Sciences, Guru Ghasidas University, Bilaspur, 495 009, (C.G.), India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3735-8861","authenticated-orcid":true,"given":"Priya","family":"Tiwari","sequence":"additional","affiliation":[{"name":"Institute of Pharmaceutical Sciences, Guru Ghasidas University, Bilaspur, 495 009, (C.G.), India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4093-4487","authenticated-orcid":true,"given":"Rakesh","family":"Kore","sequence":"additional","affiliation":[{"name":"Institute of Pharmaceutical Sciences, Guru Ghasidas University, Bilaspur, 495 009, (C.G.), India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9903-8890","authenticated-orcid":true,"given":"Ravichandran","family":"Veerasamy","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, AIMST University, Semeling, 08100 Bedong, Kedah Darul Aman, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3196-3390","authenticated-orcid":true,"given":"Achal","family":"Mishra","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Shri Shankaracharya Group of Institutions, Junwani, Bhiali (CG), India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2008-2827","authenticated-orcid":true,"given":"Harish","family":"Rajak","sequence":"additional","affiliation":[{"name":"Institute of Pharmaceutical Sciences, Guru Ghasidas University, Bilaspur, 495 009, (C.G.), India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S0140-6736(06)69113-7","volume":"368","author":"Blennow K.","year":"2006","unstructured":"Blennow K.; De Leon M.J.; Zetterberg H.; Alzheimer\u2019s disease. Lancet 2006,368(9533),387-403","journal-title":"Lancet"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/alz.12328","volume":"17","year":"2021","unstructured":"2021 Alzheimer\u2019s disease facts and figures. Alzheimers Dement Alzheimer\u2019s association2021,17(3),327-406","journal-title":"Alzheimers Dement"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12883-017-0800-y","volume":"17","author":"Tai S.Y.","year":"2017","unstructured":"Tai S.Y.; Chen C.H.; Chien C.Y.; Yang Y.H.; Cilostazol as an add-on therapy for patients with Alzheimer\u2019s disease in Taiwan: A case control study. BMC Neurol 2017,17(1),40","journal-title":"BMC Neurol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"b158","DOI":"10.1136\/bmj.b158","volume":"338","author":"Burns A.","year":"2009","unstructured":"Burns A.; Iliffe S.; Alzheimer\u2019s disease. BMJ 2009,338(feb05 1),b158","journal-title":"BMJ"},{"key":"ref=5","unstructured":"Dementia. World Health OrganizationAvailable from:   (Accessed on: 11 Feb 2022)."},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"184","DOI":"10.3390\/brainsci11020184","volume":"11","author":"Amat-ur-Rasool H.","year":"2021","unstructured":"Amat-ur-Rasool H.; Ahmed M.; Hasnain S.; Carter W.G.; Anti-Cholinesterase combination drug therapy as a potential treatment for Alzheimer\u2019s Disease. Brain Sci 2021,11(2),184","journal-title":"Brain Sci"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"595","DOI":"10.15252\/emmm.201606210","volume":"8","author":"Selkoe D.J.","year":"2016","unstructured":"Selkoe D.J.; Hardy J.; The amyloid hypothesis of Alzheimer\u2019s disease at 25 years. EMBO Mol Med 2016,8(6),595-608","journal-title":"EMBO Mol Med"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.bbadis.2004.09.008","volume":"1739","author":"Iqbal K.","year":"2005","unstructured":"Iqbal K.; Alonso A.C.; Chen S.; Chohan M.O.; El-Akkad E.; Gong C.X.; Khatoon S.; Li B.; Liu F.; Rahman A.; Tanimukai H.; Grundke I.I.; Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta 2005,1739(2-3),198-210","journal-title":"Biochim Biophys Acta"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1586\/14737175.8.11.1703","volume":"8","author":"Mufson E.J.","year":"2008","unstructured":"Mufson E.J.; Counts S.E.; Perez S.E.; Ginsberg S.D.; Cholinergic system during the progression of Alzheimer\u2019s disease: Therapeutic implications. Expert Rev Neurother 2008,8(11),1703-1718","journal-title":"Expert Rev Neurother"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3389\/fcell.2019.00197","volume":"7","author":"Uddin M.S.","year":"2019","unstructured":"Uddin M.S.; Kabir M.T.; Emerging signal regulating potential of genistein against Alzheimer\u2019s disease: A promising molecule of interest. Front Cell Dev Biol 2019,7,197","journal-title":"Front Cell Dev Biol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/nrneurol.2011.2","volume":"7","author":"Reitz C.","year":"2011","unstructured":"Reitz C.; Brayne C.; Mayeux R.; Epidemiology of Alzheimer disease. Nat Rev Neurol 2011,7(3),137-152","journal-title":"Nat Rev Neurol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s11910-014-0499-8","volume":"14","author":"Ringman J.M.","year":"2014","unstructured":"Ringman J.M.; Goate A.; Masters C.L.; Cairns N.J.; Danek A.; Graff-Radford N.; Ghetti B.; Morris J.C.; Genetic heterogeneity in Alzheimer\u2019s disease and implications for treatment strategies. Curr Neurol Neurosci Rep 2014,14(11),499","journal-title":"Curr Neurol Neurosci Rep"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1212\/01.wnl.0000252807.38124.a3","volume":"68","author":"Hirtz D.","year":"2007","unstructured":"Hirtz D.; Thurman D.J.; Gwinn H.K.; Mohamed M.; Chaudhuri A.R.; Zalutsky R.; How common are the \u201ccommon\u201d neurologic disorders? Neurology 2007,68(5),326-337","journal-title":"Neurology"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1016\/S0140-6736(05)67889-0","volume":"366","author":"Ferri C.P.","year":"2005","unstructured":"Ferri C.P.; Prince M.; Brayne C.; Brodaty H.; Fratiglioni L.; Ganguli M.; Hall K.; Hasegawa K.; Hendrie H.; Huang Y.; Jorm A.; Mathers C.; Menezes P.R.; Rimmer E.; Scazufca M.; Global prevalence of dementia: A Delphi consensus study. Lancet 2005,366(9503),2112-2117","journal-title":"Lancet"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.archger.2009.11.008","volume":"51","author":"Giordano M.","year":"2010","unstructured":"Giordano M.; Dominguez L.J.; Vitrano T.; Curatolo M.; Ferlisi A.; Di Prima A.; Belvedere M.; Barbagallo M.; Combination of intensive cognitive rehabilitation and donepezil therapy in Alzheimer\u2019s Disease (AD). Arch Gerontol Geriatr 2010,51(3),245-249","journal-title":"Arch Gerontol Geriatr"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"e12073","DOI":"10.1002\/trc2.12073","volume":"6","author":"Salloway S.P.","year":"2020","unstructured":"Salloway S.P.; Sevingy J.; Budur K.; Pederson J.T.; DeMattos R.B.; Von Rosenstiel P.; Paez A.; Evans R.; Weber C.J.; Hendrix J.A.; Worley S.; Bain L.J.; Carrillo M.C.; Advancing combination therapy for Alzheimer\u2019s disease. Alzheimers Dement 2020,6(1),e12073","journal-title":"Alzheimers Dement"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S1474-4422(13)70276-X","volume":"13","author":"Yan R.","year":"2014","unstructured":"Yan R.; Vassar R.; Targeting the \u03b2 secretase BACE1 for Alzheimer\u2019s disease therapy. Lancet Neurol 2014,13(3),319-329","journal-title":"Lancet Neurol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3233\/JAD-2010-1221","volume":"19","author":"Murphy M.P.","year":"2010","unstructured":"Murphy M.P.; LeVine H.; Alzheimer\u2019s disease and the amyloid-\u03b2 peptide. J Alzheimers Dis 2010,19(1),311-323","journal-title":"J Alzheimers Dis"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"779","DOI":"10.3233\/JAD-180766","volume":"67","author":"Cummings J.L.","year":"2019","unstructured":"Cummings J.L.; Tong G.; Ballard C.; Treatment combinations for Alzheimer\u2019s disease: Current and future pharmacotherapy options. J Alzheimers Dis 2019,67(3),779-794","journal-title":"J Alzheimers Dis"},{"key":"ref=20","year":"2015","unstructured":"Aricept (donepezil hydrochloride) Full Prescribing Information 2015","journal-title":"Aricept (donepezil hydrochloride) Full Prescribing Information"},{"key":"ref=21","year":"2015","unstructured":"Exelon (rivastigmine tartrate) Full Prescribing Information 2015","journal-title":"Exelon (rivastigmine tartrate) Full Prescribing Information"},{"key":"ref=22","year":"2016","unstructured":"Dailymed Exelon Patch (rivastigmine transdermal system) Full Prescribing Information 2016","journal-title":"Dailymed Exelon Patch (rivastigmine transdermal system) Full Prescribing Information"},{"key":"ref=23","year":"2016","unstructured":"Dailymed Razadyne (galantamine hydrobromide) 2016","journal-title":"Dailymed Razadyne (galantamine hydrobromide)"},{"key":"ref=24","year":"2014","unstructured":"Dailymed Namenda XR (memantine hydrochloride) Full Prescribing Information 2014","journal-title":"Dailymed Namenda XR (memantine hydrochloride) Full Prescribing Information"},{"key":"ref=25","year":"2016","unstructured":"Dailymed Namzaric (memantine and donepezil hydrochlorides) 2016","journal-title":"Dailymed Namzaric (memantine and donepezil hydrochlorides)"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1202753","volume":"367","author":"Bateman R.J.","year":"2012","unstructured":"Bateman R.J.; Xiong C.; Benzinger T.L.S.; Fagan A.M.; Goate A.; Fox N.C.; Marcus D.S.; Cairns N.J.; Xie X.; Blazey T.M.; Holtzman D.M.; Santacruz A.; Buckles V.; Oliver A.; Moulder K.; Aisen P.S.; Ghetti B.; Klunk W.E.; McDade E.; Martins R.N.; Masters C.L.; Mayeux R.; Ringman J.M.; Rossor M.N.; Schofield P.R.; Sperling R.A.; Salloway S.; Morris J.C.; Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease. N Engl J Med 2012,367(9),795-804","journal-title":"N Engl J Med"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40035-018-0107-y","volume":"7","author":"Du X.","year":"2018","unstructured":"Du X.; Wang X.; Geng M.; Alzheimer\u2019s disease hypothesis and related therapies. Transl Neurodegener 2018,7(1),2","journal-title":"Transl Neurodegener"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"173554","DOI":"10.1016\/j.ejphar.2020.173554","volume":"887","author":"Vaz M.","year":"2020","unstructured":"Vaz M.; Silvestre S.; Alzheimer\u2019s disease: Recent treatment strategies. Eur J Pharmacol 2020,887(887),173554","journal-title":"Eur J Pharmacol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1126\/science.1566067","volume":"256","author":"Hardy J.A.","year":"1992","unstructured":"Hardy J.A.; Higgins G.A.; Alzheimer\u2019s disease: The amyloid cascade hypothesis. Science 1992,256(5054),184-185","journal-title":"Science"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"Hardy J.","year":"2002","unstructured":"Hardy J.; Selkoe D.J.; The amyloid hypothesis of Alzheimer\u2019s disease: Progress and problems on the road to therapeutics. Science 2002,297(5580),353-356","journal-title":"Science"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1038\/nn.4018","volume":"18","author":"Musiek E.S.","year":"2015","unstructured":"Musiek E.S.; Holtzman D.M.; Three dimensions of the amyloid hypothesis: Time, space and \u2018wingmen\u2019. Nat Neurosci 2015,18(6),800-806","journal-title":"Nat Neurosci"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.npep.2015.06.008","volume":"52","author":"Barage S.H.","year":"2015","unstructured":"Barage S.H.; Sonawane K.D.; Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer\u2019s disease. Neuropeptides 2015,52,1-18","journal-title":"Neuropeptides"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/jnc.13632","volume":"139","author":"Karran E.","year":"2016","unstructured":"Karran E.; De Strooper B.; The amyloid cascade hypothesis: Are we poised for success or failure? J Neurochem 2016,139(Suppl. 2),237-252","journal-title":"J Neurochem"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","volume":"179","author":"Long J.M.","year":"2019","unstructured":"Long J.M.; Holtzman D.M.; Alzheimer disease: An update on pathobiology and treatment strategies. Cell 2019,179(2),312-339","journal-title":"Cell"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1038\/ng.2802","volume":"45","author":"Lambert J.C.","year":"2013","unstructured":"Lambert J.C.; Ibrahim-Verbaas C.A.; Harold D.; Naj A.C.; Sims R.; Bellenguez C.; Jun G.; DeStefano A.L.; Bis J.C.; Beecham G.W.; Grenier-Boley B.; Russo G.; Thornton-Wells T.A.; Jones N.; Smith A.V.; Chouraki V.; Thomas C.; Ikram M.A.; Zelenika D.; Vardarajan B.N.; Kamatani Y.; Lin C-F.; Gerrish A.; Schmidt H.; Kunkle B.; Dunstan M.L.; Ruiz A.; Bihoreau M-T.; Choi S-H.; Reitz C.; Pasquier F.; Hollingworth P.; Ramirez A.; Hanon O.; Fitzpatrick A.L.; Buxbaum J.D.; Campion D.; Crane P.K.; Baldwin C.; Becker T.; Gudnason V.; Cruchaga C.; Craig D.; Amin N.; Berr C.; Lopez O.L.; De Jager P.L.; Deramecourt V.; Johnston J.A.; Evans D.; Lovestone S.; Letenneur L.; Mor\u00f3n F.J.; Rubinsztein D.C.; Eiriksdottir G.; Sleegers K.; Goate A.M.; Fi\u00e9vet N.; Huentelman M.J.; Gill M.; Brown K.; Kamboh M.I.; Keller L.; Barberger-Gateau P.; McGuinness B.; Larson E.B.; Green R.; Myers A.J.; Dufouil C.; Todd S.; Wallon D.; Love S.; Rogaeva E.; Gallacher J.; St George-Hyslop P.; Clarimon J.; Lleo A.; Bayer A.; Tsuang D.W.; Yu L.; Tsolaki M.; Boss\u00f9 P.; Spalletta G.; Proitsi P.; Collinge J.; Sorbi S.; Sanchez-Garcia F.; Fox N.C.; Hardy J.; Naranjo M.C.D.; Bosco P.; Clarke R.; Brayne C.; Galimberti D.; Mancuso M.; Matthews F.; Moebus S.; Mecocci P.; Del Zompo M.; Maier W.; Hampel H.; Pilotto A.; Bullido M.; Panza F.; Caffarra P.; Nacmias B.; Gilbert J.R.; Mayhaus M.; Lannfelt L.; Hakonarson H.; Pichler S.; Carrasquillo M.M.; Ingelsson M.; Beekly D.; Alvarez V.; Zou F.; Valladares O.; Younkin S.G.; Coto E.; Hamilton-Nelson K.L.; Gu W.; Razquin C.; Pastor P.; Mateo I.; Owen M.J.; Faber K.M.; Jonsson P.V.; Combarros O.; O\u2019Donovan M.C.; Cantwell L.B.; Soininen H.; Blacker D.; Mead S.; Mosley T.H.; Bennett D.A.; Harris T.B.; Fratiglioni L.; Holmes C.; de Bruijn R.F.A.G.; Passmore P.; Montine T.J.; Bettens K.; Rotter J.I.; Brice A.; Morgan K.; Foroud T.M.; Kukull W.A.; Hannequin D.; Powell J.F.; Nalls M.A.; Ritchie K.; Lunetta K.L.; Kauwe J.S.K.; Boerwinkle E.; Riemenschneider M.; Boada M.; Hiltunen M.; Martin E.R.; Schmidt R.; Rujescu D.; Wang L.S.; Dartigues J.F.; Mayeux R.; Tzourio C.; Hofman A.; N\u00f6then M.M.; Graff C.; Psaty B.M.; Jones L.; Haines J.L.; Holmans P.A.; Lathrop M.; Pericak-Vance M.A.; Launer L.J.; Farrer L.A.; van Duijn C.M.; Van Broeckhoven C.; Moskvina V.; Seshadri S.; Williams J.; Schellenberg G.D.; Amouyel P.; Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer\u2019s disease. Nat Genet 2013,45(12),1452-1458","journal-title":"Nat Genet"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0896-6273(00)81109-5","volume":"24","author":"Mesulam M.M.","year":"1999","unstructured":"Mesulam M.M.; Neuroplasticity failure in Alzheimer\u2019s disease: Bridging the gap between plaques and tangles. Neuron 1999,24(3),521-529","journal-title":"Neuron"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/NEN.0b013e31825018f7","volume":"71","author":"Nelson P.T.","year":"2012","unstructured":"Nelson P.T.; Alafuzoff I.; Bigio E.H.; Bouras C.; Braak H.; Cairns N.J.; Castellani R.J.; Crain B.J.; Davies P.; Tredici K.D.; Duyckaerts C.; Frosch M.P.; Haroutunian V.; Hof P.R.; Hulette C.M.; Hyman B.T.; Iwatsubo T.; Jellinger K.A.; Jicha G.A.; K\u00f6vari E.; Kukull W.A.; Leverenz J.B.; Love S.; Mackenzie I.R.; Mann D.M.; Masliah E.; McKee A.C.; Montine T.J.; Morris J.C.; Schneider J.A.; Sonnen J.A.; Thal D.R.; Trojanowski J.Q.; Troncoso J.C.; Wisniewski T.; Woltjer R.L.; Beach T.G.; Correlation of Alzheimer disease neuropathologic changes with cognitive status: A review of the literature. J Neuropathol Exp Neurol 2012,71(5),362-381","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41583-019-0240-3","volume":"21","author":"Van Der Kant R.","year":"2020","unstructured":"Van Der Kant R.; Goldstein L.S.B.; Ossenkoppele R.; Amyloid-\u03b2-independent regulators of tau pathology in Alzheimer disease. Nat Rev Neurosci 2020,21(1),21-35","journal-title":"Nat Rev Neurosci"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"Braak H.","year":"1991","unstructured":"Braak H.; Braak E.; Neuropathological stageing of Alzheimer related changes. Acta Neuropathol 1991,82(4),239-259","journal-title":"Acta Neuropathol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.neuron.2018.02.015","volume":"97","author":"Sato C.","year":"2018","unstructured":"Sato C.; Barth\u00e9lemy N.R.; Mawuenyega K.G.; Patterson B.W.; Gordon B.A.; Jockel-Balsarotti J.; Sullivan M.; Crisp M.J.; Kasten T.; Kirmess K.M.; Kanaan N.M.; Yarasheski K.E.; Baker N.A.; Benzinger T.L.S.; Miller T.M.; Karch C.M.; Bateman R.J.; Tau kinetics in neurons and the human central nervous system. Neuron 2018,97(6),1284-1298.e7","journal-title":"Neuron"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"9316","DOI":"10.1074\/jbc.REV119.008031","volume":"294","author":"Lippens G.","year":"2019","unstructured":"Lippens G.; Gigant B.; Elucidating Tau function and dysfunction in the era of cryo-EM. J Biol Chem 2019,294(24),9316-9325","journal-title":"J Biol Chem"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"283","DOI":"10.2174\/1567205014666170417111859","volume":"15","author":"Gao Y.","year":"2018","unstructured":"Gao Y.; Tan L.; Yu J.T.; Tan L.; Tau in Alzheimer\u2019s disease: Mechanisms and therapeutic strategies. Curr Alzheimer Res 2018,15(3),283-300","journal-title":"Curr Alzheimer Res"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3390\/biomedicines9050524","volume":"9","author":"Onyango I.G.","year":"2021","unstructured":"Onyango I.G.; Jauregui G.V.; \u010carn\u00e1 M.; Bennett J.P.; Stokin G.B.; Neuroinflammation in Alzheimer\u2019s disease. Biomedicines 2021,9(5),524","journal-title":"Biomedicines"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s11011-022-00953-2","volume":"37","author":"De Sousa R.A.L.","year":"2022","unstructured":"De Sousa R.A.L.; Reactive gliosis in Alzheimer\u2019s disease: A crucial role for cognitive impairment and memory loss. Metab Brain Dis 2022,37(4),851-857","journal-title":"Metab Brain Dis"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.3390\/ijms22052342","volume":"22","author":"Piccioni G.","year":"2021","unstructured":"Piccioni G.; Mango D.; Saidi A.; Corbo M.; Nistic\u00f2 R.; Targeting microglia synapse interactions in Alzheimer\u2019s disease. Int J Mol Sci 2021,22(5),2342","journal-title":"Int J Mol Sci"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3389\/fnagi.2015.00099","volume":"7","author":"Avila J.","year":"2015","unstructured":"Avila J.; G\u00f3mez R.A.; Bol\u00f3s M.; AD genetic risk factors and tau spreading. Front Aging Neurosci 2015,7,99","journal-title":"Front Aging Neurosci"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3390\/ijms19010325","volume":"19","author":"Penke B.","year":"2018","unstructured":"Penke B.; Bog\u00e1r F.; Crul T.; S\u00e1ntha M.; T\u00f3th M.; V\u00edgh L.; Heat shock proteins and autophagy pathways in neuroprotection: From molecular bases to pharmacological interventions. Int J Mol Sci 2018,19(1),325","journal-title":"Int J Mol Sci"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1096\/fj.05-3735fje","volume":"19","author":"Caspersen C.","year":"2005","unstructured":"Caspersen C.; Wang N.; Yao J.; Sosunov A.; Chen X.; Lustbader J.W.; Xu H.W.; Stern D.; McKhann G.; Du Yan S.; Mitochondrial A\u03b2: A potential focal point for neuronal metabolic dysfunction in Alzheimer\u2019s disease. FASEB J 2005,19(14),2040-2041","journal-title":"FASEB J"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"15703","DOI":"10.1523\/JNEUROSCI.0552-11.2011","volume":"31","author":"McManus M.J.","year":"2011","unstructured":"McManus M.J.; Murphy M.P.; Franklin J.L.; The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer\u2019s disease. J Neurosci 2011,31(44),15703-15715","journal-title":"J Neurosci"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.3390\/molecules27061816","volume":"27","author":"Chen Z.R.","year":"2022","unstructured":"Chen Z.R.; Huang J.B.; Yang S.L.; Hong F.F.; Role of cholinergic signaling in Alzheimer\u2019s disease. Molecules 2022,27(6),1816","journal-title":"Molecules"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.biopha.2018.06.147","volume":"106","author":"Agatonovic K.S.","year":"2018","unstructured":"Agatonovic K.S.; Kettle C.; Morton D.W.; A molecular approach in drug development for Alzheimer\u2019s disease. Biomed Pharmacother 2018,106,553-565","journal-title":"Biomed Pharmacother"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1080\/14656566.2018.1519022","volume":"19","author":"Calhoun A.","year":"2018","unstructured":"Calhoun A.; King C.; Khoury R.; Grossberg G.T.; An evaluation of memantine ER + donepezil for the treatment of Alzheimer\u2019s disease. Expert Opin Pharmacother 2018,19(15),1711-1717","journal-title":"Expert Opin Pharmacother"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/j.1527-3458.2001.tb00204.x","volume":"7","author":"Shigeta M.","year":"2001","unstructured":"Shigeta M.; Homma A.; Donepezil for Alzheimer\u2019s disease: Pharmacodynamic, pharmacokinetic, and clinical profiles. CNS Drug Rev 2001,7(4),353-368","journal-title":"CNS Drug Rev"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1124\/jpet.102.041616","volume":"306","author":"Terry A.V.","year":"2003","unstructured":"Terry A.V.; Buccafusco J.J.; The cholinergic hypothesis of age and Alzheimer\u2019s disease-related cognitive deficits: Recent challenges and their implications for novel drug development. J Pharmacol Exp Ther 2003,306(3),821-827","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=55","author":"Namenda XR","year":"2010","unstructured":"Namenda XR; (memantine hydrochloride) drug approval package. Available from: 2010"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1007\/s12640-013-9398-z","volume":"24","author":"Parsons C.G.","year":"2013","unstructured":"Parsons C.G.; Danysz W.; Dekundy A.; Pulte I.; Memantine and cholinesterase inhibitors: Complementary mechanisms in the treatment of Alzheimer\u2019s disease. Neurotox Res 2013,24(3),358-369","journal-title":"Neurotox Res"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"539","DOI":"10.2165\/11591860-000000000-00000","volume":"28","author":"Patel L.","year":"2011","unstructured":"Patel L.; Grossberg G.T.; Combination therapy for Alzheimer\u2019s disease. Drugs Aging 2011,28(7),539-546","journal-title":"Drugs Aging"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.3390\/ijms21093272","volume":"21","author":"Kabir M.T.","year":"2020","unstructured":"Kabir M.T.; Uddin M.S.; Mamun A.A.; Jeandet P.; Aleya L.; Mansouri R.A.; Ashraf G.M.; Mathew B.; Bin-Jumah M.N.; Abdel D.M.M.; Combination drug therapy for the management of Alzheimer\u2019s disease. Int J Mol Sci 2020,21(9),3272","journal-title":"Int J Mol Sci"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"298","DOI":"10.2174\/1570159X11311030005","volume":"11","author":"Posadas I.","year":"2013","unstructured":"Posadas I.; L\u00f3pez H.B.; Ce\u00f1a V.; Nicotinic receptors in neurodegeneration. Curr Neuropharmacol 2013,11(3),298-314","journal-title":"Curr Neuropharmacol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.neuropharm.2006.04.007","volume":"51","author":"Takada T.Y.","year":"2006","unstructured":"Takada T.Y.; Kume T.; Sugimoto M.; Katsuki H.; Sugimoto H.; Akaike A.; Acetylcholinesterase inhibitors used in treatment of Alzheimer\u2019s disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade. Neuropharmacology 2006,51(3),474-486","journal-title":"Neuropharmacology"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"9708","DOI":"10.1021\/jm3009458","volume":"55","author":"Simoni E.","year":"2012","unstructured":"Simoni E.; Daniele S.; Bottegoni G.; Pizzirani D.; Trincavelli M.L.; Goldoni L.; Tarozzo G.; Reggiani A.; Martini C.; Piomelli D.; Melchiorre C.; Rosini M.; Cavalli A.; Combining galantamine and memantine in multitargeted, new chemical entities potentially useful in Alzheimer\u2019s disease. J Med Chem 2012,55(22),9708-9721","journal-title":"J Med Chem"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/brb3.118","volume":"3","author":"Lopes J.P.","year":"2013","unstructured":"Lopes J.P.; Tarozzo G.; Reggiani A.; Piomelli D.; Cavalli A.; Galantamine potentiates the neuroprotective effect of memantine against NMDA-induced excitotoxicity. Brain Behav 2013,3(2),67-74","journal-title":"Brain Behav"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"4381","DOI":"10.1021\/jm800577j","volume":"51","author":"Rosini M.","year":"2008","unstructured":"Rosini M.; Simoni E.; Bartolini M.; Cavalli A.; Ceccarini L.; Pascu N.; McClymont D.W.; Tarozzi A.; Bolognesi M.L.; Minarini A.; Tumiatti V.; Andrisano V.; Mellor I.R.; Melchiorre C.; Inhibition of acetylcholinesterase, beta-amyloid aggregation, and NMDA receptors in Alzheimer\u2019s disease: A promising direction for the multi-target-directed ligands gold rush. J Med Chem 2008,51(15),4381-4384","journal-title":"J Med Chem"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/nrd1958","volume":"5","author":"Lipton S.A.","year":"2006","unstructured":"Lipton S.A.; Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond. Nat Rev Drug Discov 2006,5(2),160-170","journal-title":"Nat Rev Drug Discov"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/364626a0","volume":"364","author":"Lipton S.A.","year":"1993","unstructured":"Lipton S.A.; Choi Y.B.; Pan Z.H.; Lei S.Z.; Chen H.S.V.; Sucher N.J.; Loscalzo J.; Singel D.J.; Stamler J.S.; A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds. Nature 1993,364(6438),626-632","journal-title":"Nature"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3390\/ph7020113","volume":"7","author":"Zheng H.","year":"2014","unstructured":"Zheng H.; Fridkin M.; Youdim M.; From single target to multitarget\/network therapeutics in Alzheimer\u2019s therapy. Pharmaceuticals 2014,7(2),113-135","journal-title":"Pharmaceuticals"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1093\/brain\/awq056","volume":"133","author":"Serrano P.A.","year":"2010","unstructured":"Serrano P.A.; William C.M.; Ferrer I.; Uro C.E.; Delisle M.B.; Maurage C.A.; Hock C.; Nitsch R.M.; Masliah E.; Growdon J.H.; Frosch M.P.; Hyman B.T.; Beneficial effect of human anti-amyloid-\u03b2 active immunization on neurite morphology and Tau pathology. Brain 2010,133(5),1312-1327","journal-title":"Brain"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S1474-4422(13)70014-0","volume":"12","author":"Dodel R.","year":"2013","unstructured":"Dodel R.; Rominger A.; Bartenstein P.; Barkhof F.; Blennow K.; F\u00f6rster S.; Winter Y.; Bach J.P.; Popp J.; Alferink J.; Wiltfang J.; Buerger K.; Otto M.; Antuono P.; Jacoby M.; Richter R.; Stevens J.; Melamed I.; Goldstein J.; Haag S.; Wietek S.; Farlow M.; Jessen F.; Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer\u2019s disease: A phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol 2013,12(3),233-243","journal-title":"Lancet Neurol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1002\/cmdc.201600014","volume":"11","author":"Prati F.","year":"2016","unstructured":"Prati F.; Bergamini C.; Fato R.; Soukup O.; Korabecny J.; Andrisano V.; Bartolini M.; Bolognesi M.L.; Novel 8-hydroxyquinoline derivatives as multitarget compounds for the treatment of Alzheimer\u2019s disease. ChemMedChem 2016,11(12),1284-1295","journal-title":"ChemMedChem"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/S0006-8993(99)02096-X","volume":"852","author":"Suh S.W.","year":"2000","unstructured":"Suh S.W.; Jensen K.B.; Jensen M.S.; Silva D.S.; Kesslak P.J.; Danscher G.; Frederickson C.J.; Histochemically reactive zinc in amyloid plaques, angiopathy, and degenerating neurons of Alzheimer\u2019s diseased brains. Brain Res 2000,852(2),274-278","journal-title":"Brain Res"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"20466","DOI":"10.1074\/jbc.M100175200","volume":"276","author":"Curtain C.C.","year":"2001","unstructured":"Curtain C.C.; Ali F.; Volitakis I.; Cherny R.A.; Norton R.S.; Beyreuther K.; Barrow C.J.; Masters C.L.; Bush A.I.; Barnham K.J.; Alzheimer\u2019s disease amyloid-beta binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits. J Biol Chem 2001,276(23),20466-20473","journal-title":"J Biol Chem"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"4927","DOI":"10.1021\/jm100329q","volume":"53","author":"Fern\u00e1ndez B.M.I.","year":"2010","unstructured":"Fern\u00e1ndez B.M.I.; P\u00e9rez C.; Gonz\u00e1lez M.G.C.; Conde S.; L\u00f3pez M.G.; Villarroya M.; Garc\u00eda A.G.; Rodr\u00edguez F.M.I.; Novel tacrine-8-hydroxyquinoline hybrids as multifunctional agents for the treatment of Alzheimer\u2019s disease, with neuroprotective, cholinergic, antioxidant, and copper-complexing properties. J Med Chem 2010,53(13),4927-4937","journal-title":"J Med Chem"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1517\/14728222.2016.1121237","volume":"20","author":"Pe\u00f1a A.E.","year":"2016","unstructured":"Pe\u00f1a A.E.; Prati F.; Massenzio F.; Virgili M.; Contestabile A.; Bolognesi M.L.; Monti B.; Changing paradigm to target microglia in neurodegenerative diseases: From anti-inflammatory strategy to active immunomodulation. Expert Opin Ther Targets 2016,20(5),627-640","journal-title":"Expert Opin Ther Targets"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/978-3-7091-6301-6_10","volume":"10","author":"Weinstock M.","year":"2000","unstructured":"Weinstock M.; Bejar C.; Wang R-H.; Poltyrev T.; Gross A.; Finberg J.P.M.; Youdim M.B.H.; TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer\u2019s disease. Advances in Research on Neurodegeneration 2000,10,157-169","journal-title":"Advances in Research on Neurodegeneration"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s12031-008-9139-6","volume":"37","author":"Bar A.O.","year":"2009","unstructured":"Bar A.O.; Weinreb O.; Amit T.; Youdim M.B.H.; The novel cholinesterase-monoamine oxidase inhibitor and antioxidant, ladostigil, confers neuroprotection in neuroblastoma cells and aged rats. J Mol Neurosci 2009,37(2),135-145","journal-title":"J Mol Neurosci"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1111\/j.1471-4159.2004.02425.x","volume":"89","author":"Bar A.O.","year":"2004","unstructured":"Bar A.O.; Yogev F.M.; Amit T.; Sagi Y.; Youdim M.B.H.; Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo. J Neurochem 2004,89(5),1119-1125","journal-title":"J Neurochem"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.pneurobio.2010.06.008","volume":"92","author":"Weinreb O.","year":"2010","unstructured":"Weinreb O.; Amit T.; Bar-Am O.; Youdim M.B.H.; Rasagiline: A novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Prog Neurobiol 2010,92(3),330-344","journal-title":"Prog Neurobiol"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"509","DOI":"10.3233\/JAD-2010-1390","volume":"20","author":"Faux N.G.","year":"2010","unstructured":"Faux N.G.; Ritchie C.W.; Gunn A.; Rembach A.; Tsatsanis A.; Bedo J.; Harrison J.; Lannfelt L.; Blennow K.; Zetterberg H.; Ingelsson M.; Masters C.L.; Tanzi R.E.; Cummings J.L.; Herd C.M.; Bush A.I.; PBT2 rapidly improves cognition in Alzheimer\u2019s Disease: Additional phase II analyses. J Alzheimers Dis 2010,20(2),509-516","journal-title":"J Alzheimers Dis"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1021\/ar500152x","volume":"47","author":"Savelieff M.G.","year":"2014","unstructured":"Savelieff M.G.; DeToma A.S.; Derrick J.S.; Lim M.H.; The ongoing search for small molecules to study metal-associated amyloid-\u03b2 species in Alzheimer\u2019s disease. Acc Chem Res 2014,47(8),2475-2482","journal-title":"Acc Chem Res"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1471-4159.2005.03341.x","volume":"95","author":"Gal S.","year":"2005","unstructured":"Gal S.; Zheng H.; Fridkin M.; Youdim M.B.H.; Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion. J Neurochem 2005,95(1),79-88","journal-title":"J Neurochem"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/j.1471-4159.2005.03340.x","volume":"95","author":"Zheng H.","year":"2005","unstructured":"Zheng H.; Gal S.; Weiner L.M.; Bar A.O.; Warshawsky A.; Fridkin M.; Youdim M.B.H.; Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: In vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J Neurochem 2005,95(1),68-78","journal-title":"J Neurochem"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s12035-012-8304-7","volume":"46","author":"Kupershmidt L.","year":"2012","unstructured":"Kupershmidt L.; Amit T.; Bar-Am O.; Weinreb O.; Youdim M.B.H.; Multi-target, neuroprotective and neurorestorative M30 improves cognitive impairment and reduces Alzheimer\u2019s-like neuropathology and age-related alterations in mice. Mol Neurobiol 2012,46(1),217-220","journal-title":"Mol Neurobiol"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.mad.2012.03.001","volume":"133","author":"Kupershmidt L.","year":"2012","unstructured":"Kupershmidt L.; Amit T.; Bar A.O.; Youdim M.B.H.; Weinreb O.; Neuroprotection by the multitarget iron chelator M30 on age-related alterations in mice. Mech Ageing Dev 2012,133(5),267-274","journal-title":"Mech Ageing Dev"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.brainres.2018.01.001","volume":"1702","author":"Gannon M.","year":"2019","unstructured":"Gannon M.; Wang Q.; Complex noradrenergic dysfunction in Alzheimer\u2019s disease: Low norepinephrine input is not always to blame. Brain Res 2019,1702,12-16","journal-title":"Brain Res"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3389\/fnins.2015.00220","volume":"9","author":"Gannon M.","year":"2015","unstructured":"Gannon M.; Che P.; Chen Y.; Jiao K.; Roberson E.D.; Wang Q.; Noradrenergic dysfunction in Alzheimer\u2019s disease. Front Neurosci 2015,9,220","journal-title":"Front Neurosci"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1097\/JGP.0b013e3181aad585","volume":"17","author":"Mohs R.C.","year":"2009","unstructured":"Mohs R.C.; Shiovitz T.M.; Tariot P.N.; Porsteinsson A.P.; Baker K.D.; Feldman P.D.; Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study. Am J Geriatr Psychiatry 2009,17(9),752-759","journal-title":"Am J Geriatr Psychiatry"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41582-018-0013-z","volume":"14","author":"Congdon E.E.","year":"2018","unstructured":"Congdon E.E.; Sigurdsson E.M.; Tau-targeting therapies for Alzheimer disease. Nat Rev Neurol 2018,14(7),399-415","journal-title":"Nat Rev Neurol"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1212\/WNL.0b013e318230a16c","volume":"77","author":"Fleisher A.S.","year":"2011","unstructured":"Fleisher A.S.; Truran D.; Mai J.T.; Langbaum J.B.S.; Aisen P.S.; Cummings J.L.; Jack C.R.; Weiner M.W.; Thomas R.G.; Schneider L.S.; Tariot P.N.; Chronic divalproex sodium use and brain atrophy in Alzheimer disease. Neurology 2011,77(13),1263-1271","journal-title":"Neurology"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1001\/archgenpsychiatry.2011.72","volume":"68","author":"Tariot P.N.","year":"2011","unstructured":"Tariot P.N.; Schneider L.S.; Cummings J.; Thomas R.G.; Raman R.; Jakimovich L.J.; Loy R.; Bartocci B.; Fleisher A.; Ismail M.S.; Porsteinsson A.; Weiner M.; Jack C.R.; Thal L.; Aisen P.S.; Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch Gen Psychiatry 2011,68(8),853-861","journal-title":"Arch Gen Psychiatry"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.neurobiolaging.2006.02.012","volume":"28","author":"\u00c1lvarez A.","year":"2007","unstructured":"\u00c1lvarez A.; Cacabelos R.; Sanpedro C.; Garc\u00eda-Fantini M.; Aleixandre M.; Serum TNF-alpha levels are increased and correlate negatively with free IGF-I in Alzheimer disease. Neurobiol Aging 2007,28(4),533-536","journal-title":"Neurobiol Aging"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"340","DOI":"10.2174\/156720507781788855","volume":"4","author":"Mufson E.","year":"2007","unstructured":"Mufson E.; Counts S.; Fahnestock M.; Ginsberg S.; Cholinotrophic molecular substrates of mild cognitive impairment in the elderly. Curr Alzheimer Res 2007,4(4),340-350","journal-title":"Curr Alzheimer Res"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/j.1601-183X.2007.00378.x","volume":"7","author":"Schindowski K.","year":"2008","unstructured":"Schindowski K.; Belarbi K.; Bu\u00e9e L.; Neurotrophic factors in Alzheimer\u2019s disease: Role of axonal transport. Proceedings of the Genes, Brain and Behavior 2008,7,43-56","journal-title":"Proceedings of the Genes, Brain and Behavior"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"583","DOI":"10.2174\/156720511796391863","volume":"8","author":"Alvarez X.A.","year":"2011","unstructured":"Alvarez X.A.; Cacabelos R.; Sampedro C.; Couceiro V.; Aleixandre M.; Vargas M.; Linares C.; Granizo E.; Garc\u00eda F.M.; Baurecht W.; Doppler E.; Moessler H.; Combination treatment in Alzheimer\u2019s disease: Results of a randomized, controlled trial with cerebrolysin and donepezil. Curr Alzheimer Res 2011,8(5),583-591","journal-title":"Curr Alzheimer Res"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/j.1476-5381.2009.00249.x","volume":"158","author":"Martel J.C.","year":"2009","unstructured":"Martel J.C.; Assi\u00e9 M.B.; Bardin L.; Depoort\u00e8re R.; Cussac D.; Newman T.A.; 5-HT 1A receptors are involved in the effects of xaliproden on G-protein activation, neurotransmitter release and nociception. Br J Pharmacol 2009,158(1),232-242","journal-title":"Br J Pharmacol"},{"key":"ref=95","unstructured":"Study of xaliproden (SR57746A) in patients with mild-tomoderate Dementia of the Alzheimer's type. NCT00104013, Available from:  (Accessed on: 16 Feb 2022)."},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1212\/01.wnl.0000335163.88054.e7","volume":"71","author":"Sevigny J.J.","year":"2008","unstructured":"Sevigny J.J.; Ryan J.M.; van Dyck C.H.; Peng Y.; Lines C.R.; Nessly M.L.; Growth hormone secretagogue MK-677: No clinical effect on AD progression in a randomized trial. Neurology 2008,71(21),1702-1708","journal-title":"Neurology"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"136","DOI":"10.6000\/1927-5951.2017.07.03.10","volume":"7","author":"Yesmin B.","year":"2017","unstructured":"Yesmin B.; Oscar H.C.; Begum M.M.; Begum Y.; Herrera C.O.; Islam M.M.; Abdel D.M.M.; Inspection of phytochemical content and in vitro antioxidant profile of Gnaphalium luteoalbum L.: An unexplored phytomedicine. J Pharm Nutr Sci 2017,7(3),136-146","journal-title":"J Pharm Nutr Sci"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.13005\/bpj\/1229","volume":"10","author":"Hossain M.S.","year":"2017","unstructured":"Hossain M.S.; Uddin M.S.; Kabir M.T.; Begum M.M.; Koushal P.; Herrera C.O.; Akter R.; Asaduzzaman M.; Abdel D.M.M.; In vitro screening for phytochemicals and antioxidant activities of Syngonium podophyllum L.: An incredible therapeutic plant. Biomed Pharmacol J 2017,10(3),1267-1277","journal-title":"Biomed Pharmacol J"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"443","DOI":"10.4103\/1995-7645.237189","volume":"11","author":"Uddin M.","year":"2018","unstructured":"Uddin M.; Hossain M.; Al Mamun A.; Tewari D.; Asaduzzaman M.; Islam M.; Abdel D.M.; Phytochemical analysis and antioxidant profile of methanolic extract of seed, pulp and peel of Baccaurea ramiflora Lour. Asian Pac J Trop Med 2018,11(7),443","journal-title":"Asian Pac J Trop Med"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"120","DOI":"10.6000\/1927-5951.2018.08.03.6","volume":"8","author":"Imon R.","year":"2018","unstructured":"Imon R.; Devesh T.; Kabir M.T.; Rahman I.; Tewari D.; Jamiruddin M.R.; Al Mamun A.; Phytochemical screening and antioxidant profile of Syngonium podophyllum Schott stems: A fecund phytopharmakon. J Pharm Nutr Sci 2018,8(3),120-128","journal-title":"J Pharm Nutr Sci"},{"key":"ref=101","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/978-981-13-9636-6_5","author":"Uddin M.S.","year":"2019","unstructured":"Uddin M.S.; Kabir M.T.; Oxidative stress in Alzheimer\u2019s disease: Molecular hallmarks of underlying vulnerability. Biological, Diagnostic and Therapeutic Advances in Alzheimer\u2019s Disease 2019,91-115","journal-title":"Biological, Diagnostic and Therapeutic Advances in Alzheimer\u2019s Disease"},{"key":"ref=102","author":"Uddin M.S.","year":"2019","unstructured":"Uddin M.S.; Upaganlawar A.B.;  Oxidative Stress and Antioxidant Defense: Biomedical Value in Health and Diseases 2019","journal-title":"Oxidative Stress and Antioxidant Defense: Biomedical Value in Health and Diseases"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"50","DOI":"10.6000\/2292-2598.2017.05.02.3","volume":"5","author":"Uddin M.","year":"2017","unstructured":"Uddin M.; Rahman A.; Haque A.; Mian M.; Sufian M.; Rahman M.; Ali Y.; Rafe M.; Abdel D.M.; Uddin M.; Asaduzzaman M.; In vitro screening for antioxidant and anticholinesterase effects of Uvaria littoralis Blume.: A nootropic phytotherapeutic remedy. J. Intellect. Disabil. \u2013. Diagn Treat 2017,5(2),50-60","journal-title":"Diagn Treat"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1056\/NEJM199704243361704","volume":"336","author":"Sano M.","year":"1997","unstructured":"Sano M.; Ernesto C.; Thomas R.G.; Klauber M.R.; Schafer K.; Grundman M.; Woodbury P.; Growdon J.; Cotman C.W.; Pfeiffer E.; Schneider L.S.; Thal L.J.; A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer\u2019s disease. The Alzheimer\u2019s disease cooperative study. N Engl J Med 1997,336(17),1216-1222","journal-title":"N Engl J Med"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1097\/00002093-200304000-00010","volume":"17","author":"Klatte E.T.","year":"2003","unstructured":"Klatte E.T.; Scharre D.W.; Nagaraja H.N.; Davis R.A.; Beversdorf D.Q.; Combination therapy of donepezil and vitamin E in Alzheimer disease. Alzheimer Dis Assoc Disord 2003,17(2),113-116","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1001\/jama.300.15.1774","volume":"300","author":"Aisen P.S.","year":"2008","unstructured":"Aisen P.S.; Schneider L.S.; Sano M.; Diaz A.R.; Van Dyck C.H.; Weiner M.F.; Bottiglieri T.; Jin S.; Stokes K.T.; Thomas R.G.; Thal L.J.; High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: A randomized controlled trial. JAMA 2008,300(15),1774-1783","journal-title":"JAMA"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1001\/jama.2010.1510","volume":"304","author":"Quinn J.F.","year":"2010","unstructured":"Quinn J.F.; Raman R.; Thomas R.G.; Yurko M.K.; Nelson E.B.; Van Dyck C.; Galvin J.E.; Emond J.; Jack C.R.; Weiner M.; Shinto L.; Aisen P.S.; Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: A randomized trial. JAMA 2010,304(17),1903-1911","journal-title":"JAMA"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1001\/archneur.63.10.1402","volume":"63","author":"Freund L.Y.","year":"2006","unstructured":"Freund L.Y.; Eriksdotter J.M.; Cederholm T.; Basun H.; Fax\u00e9n I.G.; Garlind A.; Vedin I.; Vessby B.; Wahlund L.O.; Palmblad J.; Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: A randomized double-blind trial. Arch Neurol 2006,63(10),1402-1408","journal-title":"Arch Neurol"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"1","DOI":"10.9734\/ARRB\/2017\/35692","volume":"16","author":"Hossain M.","year":"2017","unstructured":"Hossain M.; Uddin M.; Kabir M.; Akhter S.; Goswami S.; Mamun A.; Herrera-Calderon O.; Abdel D.M.; Abdel D.M.M.; In vivo screening for analgesic and anti-inflammatory activities of Syngonium podophyllum L.: A remarkable herbal medicine. Annu Res Rev Biol 2017,16(3),1-12","journal-title":"Annu Res Rev Biol"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"1562038","DOI":"10.1155\/2019\/1562038","volume":"2019","author":"Begum M.M.","year":"2019","unstructured":"Begum M.M.; Islam A.; Begum R.; Uddin M.S.; Rahman M.S.; Alam S.; Akter W.; Das M.; Rahman M.S.; Imon A.H.M.R.; Ethnopharmacological inspections of organic extract of Oroxylum indicum in rat models: A promising natural gift. Evidence-based complement. Altern Med 2019,2019,1562038","journal-title":"Altern Med"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.3390\/ph3061812","volume":"3","author":"Moore A.H.","year":"2010","unstructured":"Moore A.H.; Bigbee M.J.; Boynton G.E.; Wakeham C.M.; Rosenheim H.M.; Staral C.J.; Morrissey J.L.; Hund A.K.; Non-steroidal anti-inflammatory drugs in Alzheimer\u2019s disease and Parkinson\u2019s disease: Reconsidering the role of neuroinflammation. Pharmaceuticals 2010,3(6),1812-1841","journal-title":"Pharmaceuticals"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/BF03325217","volume":"21","author":"Pasqualetti P.","year":"2009","unstructured":"Pasqualetti P.; Bonomini C.; Dal Forno G.; Paulon L.; Sinforiani E.; Marra C.; Zanetti O.; Maria Rossini P.; A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer\u2019s disease. Aging Clin Exp Res 2009,21(2),102-110","journal-title":"Aging Clin Exp Res"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000096588","volume":"23","author":"Soininen H.","year":"2007","unstructured":"Soininen H.; West C.; Robbins J.; Niculescu L.; Long-term efficacy and safety of celecoxib in Alzheimer\u2019s disease. Dement Geriatr Cogn Disord 2007,23(1),8-21","journal-title":"Dement Geriatr Cogn Disord"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1001\/jama.289.21.2819","volume":"289","author":"Aisen P.S.","year":"2003","unstructured":"Aisen P.S.; Schafer K.A.; Grundman M.; Pfeiffer E.; Sano M.; Davis K.L.; Farlow M.R.; Jin S.; Thomas R.G.; Thal L.J.; Effects of rofecoxib or naproxen vs. placebo on Alzheimer disease progression: A randomized controlled trial. JAMA 2003,289(21),2819-2826","journal-title":"JAMA"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1007\/s11011-018-0227-1","volume":"33","author":"Zhong K.L.","year":"2018","unstructured":"Zhong K.L.; Chen F.; Hong H.; Ke X.; Lv Y.G.; Tang S.S.; Zhu Y.B.; New views and possibilities of antidiabetic drugs in treating and\/or preventing mild cognitive impairment and Alzheimer\u2019s disease. Metab Brain Dis 2018,33(4),1009-1018","journal-title":"Metab Brain Dis"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jns.2009.09.022","volume":"288","author":"Plastino M.","year":"2010","unstructured":"Plastino M.; Fava A.; Pirritano D.; Cotronei P.; Sacco N.; Sperl\u00ec T.; Span\u00f2 A.; Gallo D.; Mungari P.; Consoli D.; Bosco D.; Effects of insulinic therapy on cognitive impairment in patients with Alzheimer disease and diabetes mellitus type-2. J Neurol Sci 2010,288(1-2),112-116","journal-title":"J Neurol Sci"},{"key":"ref=117","first-page":"1479","volume":"20","author":"Sharma K.","year":"2019","unstructured":"Sharma K.; Cholinesterase inhibitors as Alzheimer\u2019s therapeutics. Mol Med Rep 2019,20(2),1479-1487","journal-title":"Mol Med Rep"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jalz.2010.09.003","volume":"7","author":"Weiner M.W.","year":"2011","unstructured":"Weiner M.W.; Sadowsky C.; Saxton J.; Hofbauer R.K.; Graham S.M.; Yu S.Y.; Li S.; Hsu H.A.; Suhy J.; Fridman M.; Perhach J.L.; Magnetic resonance imaging and neuropsychological results from a trial of memantine in Alzheimer\u2019s disease. Alzheimers Dement 2011,7(4),425-435","journal-title":"Alzheimers Dement"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1136\/jnnp.2008.158964","volume":"80","author":"Lopez O.L.","year":"2009","unstructured":"Lopez O.L.; Becker J.T.; Wahed A.S.; Saxton J.; Sweet R.A.; Wolk D.A.; Klunk W.; DeKosky S.T.; Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry 2009,80(6),600-607","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"T793","DOI":"10.1016\/j.jalz.2008.05.2476","volume":"4","author":"Grossberg G.","year":"2008","unstructured":"Grossberg G.; Manes F.; Allegri R.; Gutierrez R.L.M.; Gloger S.; Xie L.; Jia X.D.; Perhach J.; Graham S.M.; P4\u2010405: A multinational, randomized, double\u2010blind, placebo\u2010controlled, parallel\u2010 group trial of memantine extended\u2010release capsule (28 mg, once daily) in patients with moderate to severe Alzheimer\u2019s disease. Alzheimers Dement 2008,4(4S_Part_24),T793","journal-title":"Alzheimers Dement"},{"key":"ref=121","first-page":"367","volume":"4","author":"Thomas S.J.","year":"2009","unstructured":"Thomas S.J.; Grossberg G.T.; Memantine: A review of studies into its safety and efficacy in treating Alzheimer\u2019s disease and other dementias. Clin Interv Aging 2009,4,367-377","journal-title":"Clin Interv Aging"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2174\/156720508783884576","volume":"5","author":"Porsteinsson A.","year":"2008","unstructured":"Porsteinsson A.; Grossberg G.; Mintzer J.; Olin J.; Memantine treatment in patients with mild to moderate Alzheimer\u2019s disease already receiving a cholinesterase inhibitor: A randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res 2008,5(1),83-89","journal-title":"Curr Alzheimer Res"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1097\/WAD.0b013e31816653bc","volume":"22","author":"Atri A.","year":"2008","unstructured":"Atri A.; Shaughnessy L.W.; Locascio J.J.; Growdon J.H.; Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 2008,22(3),209-221","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1212\/01.wnl.0000223333.42368.f1","volume":"67","author":"Cummings J.L.","year":"2006","unstructured":"Cummings J.L.; Schneider E.; Tariot P.N.; Graham S.M.; Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology 2006,67(1),57-63","journal-title":"Neurology"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/01.wad.0000213859.35355.59","volume":"20","author":"Feldman H.H.","year":"2006","unstructured":"Feldman H.H.; Schmitt F.A.; Olin J.T.; Activities of daily living in moderate-to-severe Alzheimer disease: An analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis Assoc Disord 2006,20(4),263-268","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1097\/01.wad.0000213860.35355.d4","volume":"20","author":"Schmitt F.A.","year":"2006","unstructured":"Schmitt F.A.; Van Dyck C.H.; Wichems C.H.; Olin J.T.; Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: An exploratory reanalysis. Alzheimer Dis Assoc Disord 2006,20(4),255-262","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1001\/jama.291.3.317","volume":"291","author":"Tariot P.N.","year":"2004","unstructured":"Tariot P.N.; Farlow M.R.; Grossberg G.T.; Graham S.M.; McDonald S.; Gergel I.; Memantine treatment in patients with moderate to severe Alzheimer\u2019s disease already receiving donepezil: A randomized controlled trial. JAMA 2004,291(3),317-324","journal-title":"JAMA"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1185\/03007995.2011.582484","volume":"27","author":"Choi S.H.","year":"2011","unstructured":"Choi S.H.; Park K.W.; Na D.L.; Han H.J.; Kim E.J.; Shim Y.S.; Lee J.H.; Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer\u2019s disease: A multicenter, randomized, open-label, parallel-group study. Curr Med Res Opin 2011,27(7),1375-1383","journal-title":"Curr Med Res Opin"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1159\/000100875","volume":"23","author":"Riepe M.W.","year":"2007","unstructured":"Riepe M.W.; Adler G.; Ibach B.; Weinkauf B.; Tracik F.; Gunay I.; Domain-specific improvement of cognition on memantine in patients with Alzheimer\u2019s disease treated with rivastigmine. Dement Geriatr Cogn Disord 2007,23(5),301-306","journal-title":"Dement Geriatr Cogn Disord"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/j.1368-5031.2005.00769.x","volume":"60","author":"Dantoine T.","year":"2006","unstructured":"Dantoine T.; Auriacombe S.; Sarazin M.; Becker H.; Pere J.J.; Bourdeix I.; Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer\u2019s disease who failed to benefit from previous cholinesterase inhibitor treatment. Int J Clin Pract 2006,60(1),110-118","journal-title":"Int J Clin Pract"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1185\/03007990903434914","volume":"26","author":"Farlow M.R.","year":"2010","unstructured":"Farlow M.R.; Alva G.; Meng X.; Olin J.T.; A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer\u2019s disease: A post hoc analysis. Curr Med Res Opin 2010,26(2),263-269","journal-title":"Curr Med Res Opin"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1212\/WNL.0b013e3181c67808","volume":"73","author":"Salloway S.","year":"2009","unstructured":"Salloway S.; Sperling R.; Gilman S.; Fox N.C.; Blennow K.; Raskind M.; Sabbagh M.; Honig L.S.; Doody R.; van Dyck C.H.; Mulnard R.; Barakos J.; Gregg K.M.; Liu E.; Lieberburg I.; Schenk D.; Black R.; Grundman M.; A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009,73(24),2061-2070","journal-title":"Neurology"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/S1474-4422(10)70043-0","volume":"9","author":"Rinne J.O.","year":"2010","unstructured":"Rinne J.O.; Brooks D.J.; Rossor M.N.; Fox N.C.; Bullock R.; Klunk W.E.; Mathis C.A.; Blennow K.; Barakos J.; Okello A.A.; de LIano, S.R.M.; Liu, E.; Koller, M.; Gregg, K.M.; Schenk, D.; Black, R.; Grundman, M. 11C-PiB PET assessment of change in fibrillar amyloid-\u03b2 load in patients with Alzheimer\u2019s disease treated with bapineuzumab: A phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010,9(4),363-372","journal-title":"Lancet Neurol"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1474-4422(12)70015-7","volume":"11","author":"Sperling R.","year":"2012","unstructured":"Sperling R.; Salloway S.; Brooks D.J.; Tampieri D.; Barakos J.; Fox N.C.; Raskind M.; Sabbagh M.; Honig L.S.; Porsteinsson A.P.; Lieberburg I.; Arrighi H.M.; Morris K.A.; Lu Y.; Liu E.; Gregg K.M.; Brashear H.R.; Kinney G.G.; Black R.; Grundman M.; Amyloid-related imaging abnormalities in patients with Alzheimer\u2019s disease treated with bapineuzumab: A retrospective analysis. Lancet Neurol 2012,11(3),241-249","journal-title":"Lancet Neurol"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"847","DOI":"10.4161\/hv.28183","volume":"10","author":"Fettelschoss A.","year":"2014","unstructured":"Fettelschoss A.; Zabel F.; Bachmann M.F.; Vaccination against Alzheimer disease. Hum Vaccin Immunother 2014,10(4),847-851","journal-title":"Hum Vaccin Immunother"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S0140-6736(08)61075-2","volume":"372","author":"Holmes C.","year":"2008","unstructured":"Holmes C.; Boche D.; Wilkinson D.; Yadegarfar G.; Hopkins V.; Bayer A.; Jones R.W.; Bullock R.; Love S.; Neal J.W.; Zotova E.; Nicoll J.A.R.; Long-term effects of A\u03b242 immunisation in Alzheimer\u2019s disease: Follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008,372(9634),216-223","journal-title":"Lancet"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"144","DOI":"10.2174\/156720509787602852","volume":"6","author":"Vellas B.","year":"2009","unstructured":"Vellas B.; Black R.; Thal L.; Fox N.; Daniels M.; McLennan G.; Tompkins C.; Leibman C.; Pomfret M.; Grundman M.; Long-term follow-up of patients immunized with AN1792: Reduced functional decline in antibody responders. Curr Alzheimer Res 2009,6(2),144-151","journal-title":"Curr Alzheimer Res"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.intimp.2009.10.005","volume":"10","author":"Klaver A.C.","year":"2010","unstructured":"Klaver A.C.; Finke J.M.; Digambaranath J.; Balasubramaniam M.; Loeffler D.A.; Antibody concentrations to A\u03b21\u201342 monomer and soluble oligomers in untreated and antibody\u2013antigen-dissociated intravenous immunoglobulin preparations. Int Immunopharmacol 2010,10(1),115-119","journal-title":"Int Immunopharmacol"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/j.neurobiolaging.2007.12.021","volume":"30","author":"Relkin N.R.","year":"2009","unstructured":"Relkin N.R.; Szabo P.; Adamiak B.; Burgut T.; Monthe C.; Lent R.W.; Younkin S.; Younkin L.; Schiff R.; Weksler M.E.; 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer\u2019s disease. Neurobiol Aging 2009,30(11),1728-1736","journal-title":"Neurobiol Aging"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2174\/156720511795256053","volume":"8","author":"Vellas B.","year":"2011","unstructured":"Vellas B.; Sol O.; Snyder P.J.; Ousset P.J.; Haddad R.; Maurin M.; Lemari\u00e9 J-C.; D\u00e9sir\u00e9 L.; Pando M.P.; EHT0202 in Alzheimer\u2019s disease: A 3-month, randomized, placebo-controlled, double-blind study. Curr Alzheimer Res 2011,8(2),203-212","journal-title":"Curr Alzheimer Res"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"592","DOI":"10.2174\/156720511796391935","volume":"8","author":"Harrington C.","year":"2011","unstructured":"Harrington C.; Sawchak S.; Chiang C.; Davies J.; Donovan C.; Saunders A.M.; Irizarry M.; Jeter B.; Zvartau H.M.; Van Dyck C.H.; Gold M.; Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer\u2019s disease: Two phase 3 studies. Curr Alzheimer Res 2011,8(5),592-606","journal-title":"Curr Alzheimer Res"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1212\/WNL.0b013e3181d6476a","volume":"74","author":"Feldman H.H.","year":"2010","unstructured":"Feldman H.H.; Doody R.S.; Kivipelto M.; Sparks D.L.; Waters D.D.; Jones R.W.; Schwam E.; Schindler R.; Hey H.J.; DeMicco D.A.; Breazna A.; Randomized controlled trial of atorvastatin in mild to moderate Alzheimer\u2019s disease: LEADe. Neurology 2010,74(12),956-964","journal-title":"Neurology"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1212\/WNL.0b013e318228bf11","volume":"77","author":"Sano M.","year":"2011","unstructured":"Sano M.; Bell K.L.; Galasko D.; Galvin J.E.; Thomas R.G.; Van Dyck C.H.; Aisen P.S.; A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology 2011,77(6),556-563","journal-title":"Neurology"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1001\/jama.2009.1866","volume":"302","author":"Green R.C.","year":"2009","unstructured":"Green R.C.; Schneider L.S.; Amato D.A.; Beelen A.P.; Wilcock G.; Swabb E.A.; Zavitz K.H.; Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: A randomized controlled trial. JAMA 2009,302(23),2557-2564","journal-title":"JAMA"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/S1474-4422(08)70090-5","volume":"7","author":"Wilcock G.K.","year":"2008","unstructured":"Wilcock G.K.; Black S.E.; Hendrix S.B.; Zavitz K.H.; Swabb E.A.; Laughlin M.A.; Efficacy and safety of tarenflurbil in mild to moderate Alzheimer\u2019s disease: A randomised phase II trial. Lancet Neurol 2008,7(6),483-493","journal-title":"Lancet Neurol"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1212\/WNL.60.1.148-a","volume":"60","author":"Rigaud A.S.","year":"2003","unstructured":"Rigaud A.S.; Andr\u00e9 G.; Vellas B.; Touchon J.; Pere J.J.; No additional benefit of HRT on response to rivastigmine in menopausal women with AD. Neurology 2003,60(1),148-149","journal-title":"Neurology"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"102","DOI":"10.5114\/aoms.2011.20612","volume":"1","author":"Aisen P.S.","year":"2011","unstructured":"Aisen P.S.; Gauthier S.; Ferris S.H.; Saumier D.; Haine D.; Garceau D.; Duong A.; Suhy J.; Oh J.; Lau W.C.; Sampalis J.; Tramiprosate in mild-to-moderate Alzheimer\u2019s disease \u2013 A randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study). Arch Med Sci 2011,1(1),102-111","journal-title":"Arch Med Sci"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1007\/s12603-009-0106-x","volume":"13","author":"Gauthier S.","year":"2009","unstructured":"Gauthier S.; Aisen P.S.; Ferris S.H.; Saumier D.; Duong A.; Haine D.; Garceau D.; Suhy J.; Oh J.; Lau W.; Sampalis J.; Effect of tramiprosate in patients with mild-to-moderate alzheimer\u2019s disease: Exploratory analyses of the MRI sub-group of the alphase study. J Nutr Health Aging 2009,13(6),550-557","journal-title":"J Nutr Health Aging"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1212\/WNL.0b013e3182309fa5","volume":"77","author":"Salloway S.","year":"2011","unstructured":"Salloway S.; Sperling R.; Keren R.; Porsteinsson A.P.; van Dyck C.H.; Tariot P.N.; Gilman S.; Arnold D.; Abushakra S.; Hernandez C.; Crans G.; Liang E.; Quinn G.; Bairu M.; Pastrak A.; Cedarbaum J.M.; A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. Neurology 2011,77(13),1253-1262","journal-title":"Neurology"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S1474-4422(08)70167-4","volume":"7","author":"Lannfelt L.","year":"2008","unstructured":"Lannfelt L.; Blennow K.; Zetterberg H.; Batsman S.; Ames D.; Harrison J.; Masters C.L.; Targum S.; Bush A.I.; Murdoch R.; Wilson J.; Ritchie C.W.; Safety, efficacy, and biomarker findings of PBT2 in targeting A\u03b2 as a modifying therapy for Alzheimer\u2019s disease: A phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol 2008,7(9),779-786","journal-title":"Lancet Neurol"},{"key":"ref=151","year":"2022","unstructured":"A study of semagacestat for Alzheimer\u2019s patients (Identity XT). NCT01035138 Available from:   (Accessed on: 21 April 2022).2022"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1001\/archneur.65.8.1031","volume":"65","author":"Fleisher A.S.","year":"2008","unstructured":"Fleisher A.S.; Raman R.; Siemers E.R.; Becerra L.; Clark C.M.; Dean R.A.; Farlow M.R.; Galvin J.E.; Peskind E.R.; Quinn J.F.; Sherzai A.; Sowell B.B.; Aisen P.S.; Thal L.J.; Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol 2008,65(8),1031-1038","journal-title":"Arch Neurol"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1517\/14656560903044982","volume":"10","author":"Henley D.B.","year":"2009","unstructured":"Henley D.B.; May P.C.; Dean R.A.; Siemers E.R.; Development of semagacestat (LY450139), a functional \u03b3-secretase inhibitor, for the treatment of Alzheimer\u2019s disease. Expert Opin Pharmacother 2009,10(10),1657-1664","journal-title":"Expert Opin Pharmacother"}],"container-title":["Current Topics in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1568026622666220907114443","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/208601\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1568026622666220907114443","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T18:52:30Z","timestamp":1691866350000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/208601\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":153,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1568026622666220907114443","relation":{},"ISSN":["1568-0266"],"issn-type":[{"value":"1568-0266","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-04-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-03","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}